Background Hospitalization for the first episode of heart failure with reduced ejection fraction (HFrEF) represents an important opportunity to initiate evidence-based therapies. In this study, we aimed to clarify the role of vericiguat after first hospitalization for HFrEF in routine clinical practice. Methods and Res...
H. Matsuzoe, K. Matsumura, A. Suzuki et al.· Circulation Reports· 0 citations
Background:
Mitral transcatheter valve edge-to-edge repair (M-TEER) has become a treatment option for heart failure (HF) patients with mitral regurgitation (MR) at high surgical risk. However, limited data exist for the association between hospitalization at a center providing advanced HF therapy and clinical outcom...
K. Takegawa, Y. Iwanaga, K. Kanaoka et al.· Circulation· 0 citations
Background Patients with adult congenital heart disease (ACHD) are prone to complications and usually require surgical intervention, but the surgical risk factors remain poorly defined. Methods and Results We analyzed data from April 2013 to March 2023 in the nationwide Japanese Registry of All Cardiac and Vascular Dis...
Takumi Osawa, T. Machino-Ohtsuka, Keitaro Kume et al.· Circulation Reports· 0 citations
Optimal long-term antiplatelet monotherapy in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) remains a subject of ongoing debate. In particular, it remains unclear whether different P2Y12 inhibitors provide comparable clinical benefits when used as long-term mon...
Y. Iwanaga, K. Kanaoka, K. Takegawa et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.